Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

by Maria Beconi, Omar Aziz, Kim Matthews, Lara Moumné, Catherine O'Connell, Dawn Yates, Steven Clifton, Hannah Pett, Julie Vann, Lynsey Crowley, Alan F Haughan, Donna L Smith, Ben Woodman, Gillian P Bates, Fred Brookfield, Roland W Bürli, George McAllister, Celia Dominguez, Ignacio Munoz-Sanjuan, Vahri Beaumont
Published 2012-01-01